<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336816">
  <stage>Registered</stage>
  <submitdate>4/05/2011</submitdate>
  <approvaldate>6/05/2011</approvaldate>
  <actrnumber>ACTRN12611000471987</actrnumber>
  <trial_identification>
    <studytitle>A Comparison of Recurrence After  Radical Hepatectomy in Hepatocellular Carcinoma (HCC) Patients Underwent Intraoperative Adjuvant Epirubicin therapy or Not</studytitle>
    <scientifictitle>A prospective randomized controlled trial comparing recurrence outcome of intraoperative adjuvant epirubicin therapy from gastroepiploic vein versus no adjuvant therapy for patients with hepatocellular carcinoma after radical hepatectomy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>hepatocellular carcinoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Liver</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>After the radical resection, the adjuvant group received the single injection of 20mg epirubicin from  gastroepiploic vein during the operation.</interventions>
    <comparator>After the radical resection, the no adjuvant group received the single injection of 20ml physiological saline from   gastroepiploic vein during the operation.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time   to  recurrence.
Recurrence was confirmed by dynamic contrast-enhanced Computerised Tomography scanning or selective hepatic arteriography in subjects with an elevated alpha-fetoprotein level or with a newly identified mass.</outcome>
      <timepoint>Time from curative hepatectomy to the first diagnosis of tumor recurrence</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Overall Survival  from randomization to death.
Death was confirmed by a Statement of Death or Death certificate approved by a licensed medical practitioner.</outcome>
      <timepoint>Every year after randomization for 5 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Disease-free survival (DFS)
Time from randomization to either recurrence or death. Patients alive and free of recurrence at the end of follow-up are surveyed via patient census.</outcome>
      <timepoint>Every year after randomization for 5 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.Patients with histologically proven hepatocellular carcinoma 
2.Underwent curative hepatectomy with less than 50% of the liver and with a tumor-free resection margin greater than 1 cm 
3.Postoperative decline of alpha-fetoprotein (AFP) level to less than 20 micro g/L.
4.Child-Pugh class A:normalized hepatic function(glutamic pyruvic transaminase/glutamic oxaloacetic transaminase  less than 2 times the upper normal limit; total serum bilirubin less than 34.2 micro mol/L); 
5.Normal renal function &amp; Hematological parameters (serum creatinine less than 132 micro mol/L; white blood cell (WBC) count equal to 2500×109/L; platelet count (PTL) equal to 40×109/L).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Prior therapy with chemotherapy, allergy or history of severe adverse reactions to epirubicin,  the other regrion metastases, and malignant tumors in other regions of the body over the previous five years; peripheral neuropathy, history of central nervous system diseases, abnormal electrocardiogram findings, psychiatric disorders; severe cardiac, metabolic and/or infectious diseases; active peptic ulcer disease requiring treatment, absorption disorders; Pregnant or lactating females.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>central randomisation by computer</concealment>
    <sequence>Simple randomisation by using a randomization table created by a computer software</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/06/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shanghai</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Eastern Hepatobiliary Surgery Hospital</primarysponsorname>
    <primarysponsoraddress>No.225 Changhai Road, Shanghai 200438</primarysponsoraddress>
    <primarysponsorcountry>China</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Eastern Hepatobiliary Surgery Hospital</fundingname>
      <fundingaddress>No.225 Changhai Road, Shanghai 200438</fundingaddress>
      <fundingcountry>China</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Binghua  Dai</sponsorname>
      <sponsoraddress>No.225 Changhai Road, Shanghai 200438</sponsoraddress>
      <sponsorcountry>China</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Postoperative recurrence of hepatocellular carcinoma (HCC) is a major problem that hampers the efficacy of surgical resection. To date, adjuvant chemotherapy or other adjuvant modalities have not been proven effective for HCC. We conducted a randomized controlled trial to investigate whether adjuvant therapy with epirubicin intraoperative could inhibit the recurrence of HCC after radical resection.</summary>
    <trialwebsite>nil</trialwebsite>
    <publication>nil</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics Committee of Eastern Hepatobiliary Surgery Hospital</ethicname>
      <ethicaddress>No.225 Changhai Road, Shanghai 200438</ethicaddress>
      <ethicapprovaldate>30/04/2011</ethicapprovaldate>
      <hrec>EHBH-RCT-2011-412</hrec>
      <ethicsubmitdate />
      <ethiccountry>China</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. Jiamei Yang</name>
      <address>No.225 Changhai Road, Shanghai 200438,China</address>
      <phone>+8621-81875551</phone>
      <fax />
      <email>Jmyang@smmu.edu.cn</email>
      <country>China</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr. Binghua Dai</name>
      <address>No.225 Changhai Road, Shanghai 200438,China</address>
      <phone>+86-0-13918062394</phone>
      <fax />
      <email>yehaiwen@hotmail.com</email>
      <country>China</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr. Binghua Dai</name>
      <address>No.225 Changhai Road, Shanghai 200438,China</address>
      <phone>+86-0-13918062394</phone>
      <fax>+8621-81875462</fax>
      <email>yehaiwen@hotmail.com</email>
      <country>China</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>